Bio Blast Pharma Ltd (ORPN) Releases Earnings Results, Misses Expectations By $-0.03 EPS

Bio Blast Pharma Ltd (ORPN) reported quarterly earnings results on Wednesday, May-25-2016. The company reported $-0.32 earnings per share for the quarter, missing the analyst consensus estimate by $-0.03. Analysts had a consensus of $-0.29. During the same quarter in the previous year, the company posted $-0.23 EPS.

Bio Blast Pharma Ltd opened for trading at $1.72 and hit $1.9 on the upside on Friday, eventually ending the session at $1.78, with a gain of 4.09% or 0.07 points. The heightened volatility saw the trading volume jump to 4,04,640 shares. Company has a market cap of $29,178 M.

Bio Blast Pharma Ltd. (BioBlast) is a development-stage biopharmaceutical company. The Company is focused on the identification licensing acquisition development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. The Company is advancing its Cabaletta platform product candidates through clinical development and advancing its other product candidates BB-FA BB-OTC and BBrm1 as well as its other early stage research projects through preclinical development. The Company’s three principal product candidate platforms include Protein Stabilizing Platform Read-through Platform and Mitochondrial Protein Replacement Platform. The Company is developing Cabaletta for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD); spinocerebellar ataxia type 3 (SCA3) and Spinobulbar Muscular Atrophy (SBMA). It is conducting preclinical studies of BBrm1 for the treatment of Spinal Muscular Atrophy (SMA).

Bio Blast Pharma Ltd

Leave a Reply

Bio Blast Pharma Ltd - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bio Blast Pharma Ltd. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.